Publications by authors named "Leone Bernardo"
Article Synopsis
- Triple-negative breast cancer (TNBC) poses a high risk of breast cancer-specific mortality (BCSM), and the tool 'ESTIMATE-TN' helps estimate this risk and non-breast cancer-specific mortality for better clinical decisions.
- Utilizing data from the SEER database, ESTIMATE-TN provides an interactive assessment of cumulative risks for BCSM and non-BCSM for non-metastatic cases based on patient and tumor characteristics over a 7-year period from diagnosis.
- The study included 37,293 TNBC patients, revealing specific risk percentages for different age groups and tumor characteristics, demonstrating the tool's potential in helping healthcare providers understand competing mortality risks in TNBC patients.
Article Synopsis
- Breast cancer mortality rates have significantly improved for women, but changes in survival rates for men remain unclear, prompting an evaluation of breast cancer-specific survival (BCSS) and overall survival (OS) in males over 30 years.
- A study analyzed 8,481 men diagnosed with breast cancer from 1988 to 2017, showing BCSS remained stable across three time periods, while OS improved slightly over time.
- The findings indicate no notable advancements in BCSS for men, highlighting the need for targeted efforts to enhance survival rates in male breast cancer patients.
Article Synopsis
- Neoadjuvant chemotherapy (NAC) is commonly used for treating breast cancer in women, but its effectiveness in men with breast cancer (MaBC) is not well understood, prompting this study to compare pathologic complete response (pCR) rates between MaBC and female breast cancer (FBC).
- The study analyzed data from the National Cancer Database for patients treated with NAC between 2010 and 2016, finding that FBC has higher pCR rates compared to MaBC across various tumor subtypes, indicating a significant difference in response to treatment.
- Results showed that FBC patients had twice the odds of achieving pCR compared to MaBC patients, and both groups demonstrated better overall survival (OS) rates for
Article Synopsis
- The study developed an interactive tool named 'ESTIMATE' to help assess the long-term risks of breast cancer-specific mortality (BCSM) and other mortality types in women with non-metastatic, hormone receptor-positive breast cancer.
- Using data from the SEER registry, the tool analyzes information from over 264,000 diagnosed women to provide estimates for residual mortality risks up to 20 years post-diagnosis based on individual patient characteristics.
- For instance, a woman aged 40-49 with specific cancer characteristics who has survived 7 years post-diagnosis may face a 14% risk of BCSM in the next 13 years, highlighting how ESTIMATE can assist in clinical decisions and patient discussions about breast cancer
Article Synopsis
- A study examined long-term risks of breast cancer-specific mortality (BCSM) using a large population-based cohort, focusing on data from women diagnosed between 1990 and 2005.
- The findings showed that 65% of BC deaths occurred after 5 years for hormone receptor (HR)-positive patients, compared to 28% for HR-negative patients, indicating different risk profiles for these groups.
- The study concludes that BCSM risks persist beyond 5 years and suggests that preventing both early and late recurrences should be a priority in breast cancer care.
Article Synopsis
- Male breast cancer is rare and primarily hormone receptor positive, but its tumor subtype's impact on survival rates remains unclear.
- A study using SEER data analyzed 2,389 men with invasive breast cancer, finding that different tumor subtypes significantly affected overall survival (OS) and breast cancer-specific survival (BCSS).
- Results indicated that men with triple-negative (TN) tumors had the worst survival rates among subtypes, highlighting a need for further research to address potential under-treatment and aggressive disease presentation in these cases.
Article Synopsis
- The study examined the 20-year risk of breast cancer-specific mortality (BCSM) in women with stage III breast cancer, focusing on factors affecting late deaths.
- A total of 36,500 patients diagnosed from 1990 to 2005 were analyzed, revealing that BCSM risks were significantly higher for hormone receptor-negative tumors compared to hormone receptor-positive tumors.
- The findings indicate that, even after surviving 5 years, the risk of late BCSM is influenced by factors such as tumor size, nodal status, race, age, and tumor grade.
Article Synopsis
- The study investigates how the pattern of metastatic spread in male breast cancer affects overall survival, as this has been well-established in women but not understood for men.
- Data from the SEER database involving 250 male patients with newly diagnosed metastatic breast cancer between 2010 and 2017 revealed different median overall survival rates based on the metastatic pattern, with bone-only metastases associated with the longest survival.
- The findings indicate that specific factors, such as tumor subtype and the presence of brain metastases, significantly influence survival outcomes, highlighting that brain metastases lead to a significantly poorer prognosis, particularly in younger patients.
Article Synopsis
- The study investigates how different breast cancer tumor subtypes (TS) affect overall survival (OS) across various cancer stages using data from women diagnosed between 2010 and 2013.
- A total of 166,054 patients were analyzed, revealing the distribution of TS, where HR-positive/HER2-negative tumors had the best clinical features but HR-positive/HER2-positive tumors had the highest OS in advanced stages.
- The findings highlight significant differences in OS based on TS in all four stages of breast cancer, with the results confirmed through multivariate analysis, suggesting the need for tailored treatment approaches based on tumor subtype.
Article Synopsis
- The study aimed to compare overall survival (OS) rates between male breast cancer (MBC) and female breast cancer (FBC) patients based on tumor subtype and other factors.
- It analyzed data from 1187 MBC and 166,054 FBC patients, finding that OS at 3 years was 85.6% for MBC and 90.4% for FBC, with MBC patients typically having higher grade and more advanced tumors.
- Results revealed that MBC had worse OS than FBC in early stages and especially in HR+/HER2+ subtypes, indicating men face nearly double the risk of death compared to women with the same tumor type.
Article Synopsis
- The study focuses on women diagnosed with brain metastases at the same time as breast cancer, which is a rare and complex situation.
- In the analysis of 740 patients, the median overall survival was found to be 10 months, with only 20.7% surviving at 3 years; tumor subtype significantly influenced survival rates.
- Key findings indicated that triple-negative breast cancer had the shortest median survival of 6 months, while the HR+/HER2+ subtype had the longest, at 22 months; additional factors affecting survival included age, type of tumor histology, presence of liver metastases, and marital status.
Breast cancer is a systemic disease rather than an anatomical process.
Breast Cancer Res Treat
February 2017
Article Synopsis
- The study analyzed the impact of different metastatic patterns (MP) on overall survival (OS) in women with stage IV breast cancer diagnosed initially, along with other biological and clinical factors.
- A total of 9,143 patients were evaluated, revealing significant differences in median OS based on MP, with bone-only metastases showing the best survival rates.
- Key prognostic factors influencing OS included older age, black race, tumor grade, type (triple-negative), and marital status, which could help guide treatment decisions for patients new to therapy.
Article Synopsis
- Male breast cancer (MaBC) is not well understood, especially regarding the treatment and outcomes for early-stage patients; this study analyzed characteristics, treatments, and survival rates of men with early-stage MaBC.
- The study included 1263 men diagnosed between 1988 and 2012, showing a 5-year overall survival (OS) rate of 85.1%, with older age, higher tumor grades, lack of surgery, and no lymph node examination correlating with poorer outcomes.
- Findings suggest that while men with early MaBC have generally good survival rates, there is a need to reconsider the high rates of mastectomy and extensive lymph node examination since breast conservation and fewer lymph nodes examined yield similar survival rates.
Adjuvant systemic therapy in older women with breast cancer.
Breast Cancer (Dove Med Press)
August 2016
Breast cancer in the elderly is an increasing clinical problem. In addition, ~60% of deaths from breast cancer occur in women aged 65 years and older. Despite this, older women with breast cancer have been underrepresented in clinical trials, and this has led to less than optimal evidence to guide their therapy.
View Article and Find Full Text PDFThe human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the impact of CD44 and Lewis Y antigen (LeY) on therapy resistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC), showing that these markers relate to tumor behavior and patient outcomes.
- - Data from 126 patients was analyzed, revealing that advanced disease and expression of LeY were linked to poorer survival rates in those treated with standard radiochemotherapy based on cisplatin.
- - While coexpression of CD44 and LeY was not associated with worse outcomes overall, LeY expression specifically indicated shorter disease-free and overall survival in patients receiving radiochemotherapy.
Prognostic factors in male breast cancer: a population-based study.
Breast Cancer Res Treat
April 2016
Article Synopsis
- The study investigated prognostic factors in male breast cancer (MaBC) by analyzing data from 2992 patients diagnosed between 2003 and 2012.
- Results showed that most MaBC cases were ductal, hormone receptor-positive, and early-stage, while grade I tumors were rare.
- Key findings indicated that older age, higher tumor grades, advanced disease stage, lack of surgery or radiotherapy, ER negativity, and being unmarried were linked to shorter overall survival.
Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluates the roles of ERCC1 and TUBB3 as predictive and prognostic factors in patients with locally advanced cervical squamous cell carcinoma (LACSCC) who are undergoing different chemoradiotherapy regimens.
- High expressions of ERCC1 and TUBB3 were found in a significant portion of patients, with ERCC1 linked to advanced disease stages and poorer survival outcomes in those receiving cisplatin treatment.
- The findings suggest that while ERCC1 expression can indicate patient prognosis, TUBB3 does not influence survival outcomes in patients treated with antimicrotubule therapies.
Article Synopsis
- - The study aims to assess the characteristics and prognostic implications of different tumor subtypes in male breast cancer (MaBC), specifically analyzing data from 960 patients recorded between 2010 and 2012.
- - Patients were categorized into four subtypes based on hormone receptor (HR) and HER2 status, revealing that triple-negative (TN) patients tended to be younger and had poorer outcomes compared to other subtypes.
- - Univariate and multivariate analyses showed that factors like HER2 positivity, tumor stage, and being older significantly impacted overall survival (OS), emphasizing that tumor subtype plays a vital role in prognosis alongside age and stage.
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
José Pablo Leone Julieta Leone Carlos Teodoro Vallejo Juan Eduardo Pérez Alberto Omar Romero Bernardo Amadeo Leone
Breast Cancer Res Treat
January 2014
Article Synopsis
- * After analyzing data from 126 patients over a median follow-up of 4.5 years, the two chemotherapy regimens exhibited similar objective response rates and survival outcomes, with no significant differences in disease-free or overall survival.
- * The study found that the number of pathologically involved lymph nodes was the strongest predictor of survival, and while both regimens were tolerated, CMF had more severe blood-related side effects, while FAC was linked to more hair loss.
Most cases of breast cancer are diagnosed at early stage of disease; therefore, treatment is oriented to increase the disease-free interval (DFI) and overall survival (OS). The prognosis, in comparison with other malignancies, has improved in the last decades as a result of mammographic screening. The aim of the study was to report the incidence of local and distant recurrence, DFI and OS in patients (pts) with stage I and stage II breast cancer over a period of 26 years divided into three groups.
View Article and Find Full Text PDF